Keros Therapeutics Ownership
| KROS Stock | USD 11.22 0.22 1.92% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 38 M | Current Value 37 M | Avarage Shares Outstanding 21.6 M | Quarterly Volatility 11.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Keros |
Keros Stock Ownership Analysis
About 98.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.8. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Keros Therapeutics recorded a loss per share of 5.0. The entity had not issued any dividends in recent years. Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Keros Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 97 people. To find out more about Keros Therapeutics contact Jasbir Seehra at 617 314 6297 or learn more at https://www.kerostx.com.Besides selling stocks to institutional investors, Keros Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Keros Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Keros Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Keros Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Keros Therapeutics Insider Trades History
Roughly 2.0% of Keros Therapeutics are currently held by insiders. Unlike Keros Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Keros Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Keros Therapeutics' insider trades
Keros Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Keros Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Keros Therapeutics backward and forwards among themselves. Keros Therapeutics' institutional investor refers to the entity that pools money to purchase Keros Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Millennium Management Llc | 2024-12-31 | 878.2 K | Jefferies Financial Group Inc | 2024-12-31 | 866.7 K | Citadel Advisors Llc | 2024-12-31 | 791.1 K | Geode Capital Management, Llc | 2024-12-31 | 765.4 K | Mangrove Partners | 2024-12-31 | 736.4 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 656.8 K | Redmile Group, Llc | 2024-12-31 | 552.5 K | Tcg Crossover Management, Llc | 2024-12-31 | 550 K | Goldman Sachs Group Inc | 2024-12-31 | 535.6 K | Fmr Inc | 2024-12-31 | 5.5 M | Blackrock Inc | 2024-12-31 | 2.7 M |
Keros Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Keros Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Keros Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Keros Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Keros Therapeutics Outstanding Bonds
Keros Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Keros Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Keros bonds can be classified according to their maturity, which is the date when Keros Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Keros Therapeutics Corporate Filings
8K | 6th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 7th of February 2025 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.